^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MGMT promoter methylation

    i
    Other names: MGMT, Methylated-DNA--protein-cysteine methyltransferase, 6-O-methylguanine-DNA methyltransferase, O-6-methylguanine-DNA-alkyltransferase
    Entrez ID:
    4255
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    WBSI Guided Personalized Delivery of TTFields (NCT05086497)
    Phase N/A
    Abramson Cancer Center at Penn Medicine
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    01/15/2023
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    MGMT
    |
    MGMT promoter methylation • IDH wild-type
    Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma (NRG-BN007) (NCT04396860)
    Phase 2/3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    09/01/2020
    Primary completion :
    04/13/2023
    Completion :
    03/11/2025
    PD-L1 • TMB • IDH1 • MGMT
    |
    PD-L1 expression • MGMT promoter methylation • IDH1 R132
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (NCT02287428)
    Phase 1
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    12/05/2024
    Initiation :
    11/01/2014
    Primary completion :
    06/01/2025
    Completion :
    06/01/2026
    MGMT
    |
    MGMT promoter methylation
    |
    Keytruda (pembrolizumab) • temozolomide • Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)
    LAM561 With RT and TMZ for Adults With Glioblastoma (CLINGLIO) (NCT04250922)
    Phase 2/3
    Laminar Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    12/01/2019
    Primary completion :
    10/15/2024
    Completion :
    05/30/2025
    IDH1 • MGMT
    |
    MGMT promoter methylation • IDH wild-type
    |
    temozolomide • Minerval (idroxioleic acid)
    Azeliragon in MGMT Unmethylated Glioblastoma (NCT05986851)
    Phase 2
    Cantex Pharmaceuticals
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    09/12/2023
    Primary completion :
    09/30/2024
    Completion :
    06/30/2025
    MGMT
    |
    MGMT promoter methylation • IDH wild-type
    |
    azeliragon (TTP488)
    Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma (GlioVax) (NCT03395587)
    Phase 2
    Heinrich-Heine University, Duesseldorf
    Recruiting
    Last update posted :
    05/14/2024
    Initiation :
    03/06/2018
    Primary completion :
    11/06/2026
    Completion :
    03/06/2027
    MGMT
    |
    MGMT promoter methylation • IDH wild-type
    |
    temozolomide
    A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 (ENGAGE) (NCT03776071)
    Phase 3
    Denovo Biopharma LLC
    Completed
    Last update posted :
    04/22/2024
    Initiation :
    12/16/2020
    Primary completion :
    02/29/2024
    Completion :
    02/29/2024
    MGMT
    |
    MGMT promoter methylation
    |
    temozolomide • Kinenza (enzastaurin)
    Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma (NCT04910022)
    Phase 1/2
    Nerviano Medical Sciences
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    12/01/2021
    Primary completion :
    06/30/2025
    Completion :
    11/30/2025
    EGFR • IDH1 • IDH2 • MGMT • TERT
    |
    EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation
    |
    temozolomide • lomustine • itareparib (NMS-293)
    Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma (NCT05743595)
    Phase 1
    Washington University School of Medicine
    Recruiting
    Last update posted :
    03/04/2024
    Initiation :
    10/27/2023
    Primary completion :
    01/31/2025
    Completion :
    10/31/2027
    IDH1 • IDH2 • MGMT
    |
    IDH2 mutation • MGMT promoter methylation • IDH wild-type
    |
    Zynyz (retifanlimab-dlwr) • neoantigen DNA vaccine
    Chemoradiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail GBM Patients (NCT04765514)
    Phase 2
    AHS Cancer Control Alberta
    Recruiting
    Last update posted :
    01/30/2024
    Initiation :
    07/27/2022
    Primary completion :
    06/01/2032
    Completion :
    06/01/2032
    MGMT
    |
    MGMT promoter methylation
    |
    temozolomide
    Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma (NRG-BN011) (NCT05095376)
    Phase 3
    NRG Oncology
    Recruiting
    Last update posted :
    01/10/2024
    Initiation :
    11/29/2021
    Primary completion :
    08/08/2026
    Completion :
    08/08/2031
    IDH1 • MGMT
    |
    MGMT promoter methylation • IDH1 R132H • IDH1 R132
    |
    temozolomide • lomustine
    Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) (NCT04893356)
    Phase N/A
    National Cancer Institute, Naples
    Active, not recruiting
    Last update posted :
    10/30/2023
    Initiation :
    01/20/2021
    Primary completion :
    02/28/2022
    Completion :
    01/20/2025
    MGMT
    |
    MGMT promoter methylation • MGMT expression
    |
    dacarbazine